AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25075006
Drug: Fondaparinux with
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux with unfractionated heparin (UFH)
Trial: 25075128
Drug: Afuresertib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afuresertib (125 mg per day, maximum tolerated dose)
Trial: 25075128
Drug: Afuresertib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afuresertib (doses ranging from 25 to 150 mg per day)
Trial: 25075128
Drug: Afuresertib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afuresertib (doses > 75 mg)
Trial: 31634044
Drug: MenACWY-CRM vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM vaccine
Trial: 25075833
Drug: KAE609 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 (30 mg per day for 3 days)
Trial: 25075833
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (not specified dosage or duration)
Trial: 25076364
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL)
Trial: 25076495
Drug: Diets emphasizing
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diets emphasizing tree nuts (median dose of 56 g/d)
Trial: 25077099
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate syrup (initially 0.5 mg twice daily, titrated based on weekly assessments)
Trial: 25077099
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate syrup
Trial: 25077107
Drug: Sufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient vitamin D levels (≥ 75 nmol/L)
Trial: 25077107
Drug: Insufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient vitamin D levels (< 75 nmol/L)
Trial: 25079400
Drug: Intensive oral
RxNorm normalized name: Uricalm Intensive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive oral hygiene regimen with oral hygiene products and non-surgical therapy
Trial: 25079400
Drug: Intensive oral
RxNorm normalized name: Uricalm Intensive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive oral hygiene regimen
Trial: 25080050
Drug: Isolated raised
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated raised base excess (BE) (≥ 2 mmol/L)
Trial: 25080540
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency (sTfR > 8.5 mg/L)
Trial: 25084608
Drug: Proton beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton beam radiation therapy to the surgical bed, 40 Gy in 10 fractions, once daily over 2 weeks.
Trial: 25085632
Drug: Sunitinib (Sutent)
RxNorm normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (Sutent) - a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor
Trial: 25086465
Drug: Imatinib, dacarbazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib, dacarbazine, and capecitabine regimen (imatinib 300 mg daily on days 1-21, dacarbazine 250 mg/m2 daily on days 1-3, capecitabine 500 mg/m2 twice daily on days 1-14)
Trial: 25086913
Drug: Metformin (61.2%)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (61.2%)
Trial: 25086913
Drug: Insulin (18%)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (18%)
Trial: 25090645
Drug: AS03A-H5N1 vaccine
RxNorm normalized name: influenza A virus (H5N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A-H5N1 vaccine (3.75μg hemagglutinin-antigen)
Trial: 25091263
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of each 28-day cycle plus gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15
Trial: 25091537
Drug: Aztreonam for
RxNorm normalized name: Aztreonam for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam for inhalation solution (AZLI) 75 mg 3 times daily for 28 days
Trial: 25091619
Drug: Ixabepilone 40
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 40 mg/m² on day one of a 21 day cycle
Trial: 25093475
Drug: Brief pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief pulse right unilateral electroconvulsive therapy (ECT)
Trial: 25093475
Drug: Ultrabrief pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrabrief pulse right unilateral electroconvulsive therapy (ECT)
Trial: 25099027
Drug: TACE/sorafenib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE/sorafenib combination
Trial: 25101571
Drug: Nitinol stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitinol stent treatment
Trial: 25102383
Drug: Cumulative Illness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative Illness Rating Scale-Geriatric (CIRS-G)
Trial: 25105369
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with O6BG/TMZ chemotherapy
Trial: 25105369
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls without gene therapy
Trial: 25110632
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg single dose
Trial: 25110632
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg single dose
Trial: 25110632
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg two doses
Trial: 25110632
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg two doses
Trial: 25111234
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment (median duration 4 days, range 2-7 days)
Trial: 25112732
Drug: Recombinant LCN2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant LCN2 treatment
Trial: 25113756
Drug: LCL161 (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 (1,800 mg, oral, once weekly, tablet formulation)
Trial: 25113756
Drug: LCL161 (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 (tablet formulation)
Trial: 25113756
Drug: LCL161 (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 (1,800 mg)
Trial: 25114718
Drug: anti-HER2 agents
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-HER2 agents
Trial: 25115686
Drug: Resveratrol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (1 gm daily for 12 weeks)
Trial: 25116755
Drug: Cyclophosphamide, GM-CSF-secreting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, GM-CSF-secreting breast tumor vaccine, and trastuzumab
Trial: 25117475
Drug: Cabazitaxel/cisplatin (15/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel/cisplatin (15/75 mg/m²)
Trial: 25117475
Drug: Cabazitaxel/cisplatin (20/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel/cisplatin (20/75 mg/m²)
Trial: 25117615
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1000 mg (1 h premeal)
Trial: 25117615
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1000 mg (2 h postmeal)
Trial: 25119513
Drug: Patient-therapist working
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-therapist working alliance and patient expectations of treatment benefit
Trial: 25122609
Drug: ABC294640 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC294640 (a SK2 specific inhibitor)
Trial: 25122609
Drug: ABC294640 +
RxNorm normalized name: ABC294640
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC294640 + ABT-737 (a Bcl-2 inhibitor)
Trial: 25123851
Drug: Testosterone 2%
RxNorm normalized name: TESTOSTERONE 2% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 2% solution (Axiron®), 60-mg daily morning dose applied to axillae (30 mg/axilla)
Trial: 25125727
Drug: LV end-diastolic
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV end-diastolic volume > 98 mL/m(2)
Trial: 25125727
Drug: Creatinine level
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine level > 1.49 mg/dL
Trial: 25125727
Drug: No angiotensin-inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No angiotensin-inhibition therapy
Trial: 25125727
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of all four factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Trial: 25125727
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Trial: 25126443
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs)
Trial: 25126880
Drug: Lactate level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate level more than 1.5 mEq/L
Trial: 25127916
Drug: Steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid regimen with median dosing of 55 mg/m2/day, median cumulative dose of 3,440 mg/m2 for the first episode, median duration of 21 weeks.
Trial: 25127916
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment including albumin infusions, diuretics, and acetyl salicylic acid.
Trial: 25129345
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² every 3 weeks for four cycles
Trial: 25130947
Drug: 88 μg·kg(-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 88 μg·kg(-1) of epinephrine (1:10,000) injected into the caudal epidural space
Trial: 25132507
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg vaccine
Trial: 25132507
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg vaccine
Trial: 25132507
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg vaccine
Trial: 25133198
Drug: Rifaximin 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 1.2 g/day for 15 days/month for 2 months
Trial: 25133431
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg subcutaneously for 84 days
Trial: 25135035
Drug: Pregabalin (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (100, 150, 300, or 600 mg/day)
Trial: 25135992
Drug: R2CHOP (lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R2CHOP (lenalidomide 25 mg orally per day on days 1-10 combined with standard-dose R-CHOP every 21 days for six cycles)
Trial: 25136536
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Korean white ginseng (KWG)
Trial: 25136689
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injections (5 weekly injections)
Trial: 25137424
Drug: Endometriosis lesions
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometriosis lesions with contraceptive medication
Trial: 25137427
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy leading to remission (normal IGF-1)
Trial: 25139963
Drug: Telaprevir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN alfa-2a (180 µg/week) and RBV (1000-1200 mg/day) for 12 weeks followed by peg-IFN/RBV for 32-56 weeks according to virological response at week 8
Trial: 25141112
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate (1470 ml) and mannitol (15% 200 ml) during cardiopulmonary bypass
Trial: 25142258
Drug: SGN-75 administered
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-75 administered Q3Wk at doses escalated from 0.3 to 4.5 mg/kg
Trial: 25142258
Drug: SGN-75 administered
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-75 administered weekly at doses of 0.3 or 0.6 mg/kg
Trial: 25142258
Drug: SGN-75 administered
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-75 administered Q3Wk
Trial: 25142258
Drug: SGN-75 treatment
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-75 treatment
Trial: 25142258
Drug: SGN-75 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGN-75 administration Q3Wk vs. weekly dosing
Trial: 25142486
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard ICS treatment)
Trial: 25142735
Drug: PF-04937319 (glucokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04937319 (glucokinase activator) at doses of 100 mg and 300 mg
Trial: 25143232
Drug: Multiplex method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplex method using Luminex technology to detect antibodies against 32 synthetic biotinylated peptides comprising predicted neo-antigens.
Trial: 25143374
Drug: 22-element multiple
RxNorm normalized name: Calcium, elemental
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-element multiple micronutrient powder (MNP) administered daily for 5 months
Trial: 25143487
Drug: Obinutuzumab 400
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 400 to 1200 mg (phase 1)
Trial: 25143487
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg (phase 2)
Trial: 25145344
Drug: BFR regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFR regimen (bendamustine 130 mg/m2 per day for 3 days, fludarabine, and rituximab)
Trial: 25145469
Drug: Insulin initiation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin initiation support program
Trial: 25145775
Drug: Control (Japanese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Japanese Encephalitis vaccine)
Trial: 25148882
Drug: Prenatal glucocorticoid
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal glucocorticoid treatment
Trial: 25149088
Drug: MEDI-575 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW)
Trial: 25149088
Drug: MEDI-575 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 (25 or 35 mg/kg) every 3 weeks (Q3W)
Trial: 25150798
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg once daily plus rituximab 375 mg/m² intravenously (IV) weekly during cycle 1, then once per cycle until cycle 6, followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment.
Trial: 25155588
Drug: GS-9669 100
RxNorm normalized name: GS-100
DrugBank: GS-100 (DB18337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9669 100 mg BID
Trial: 25155588
Drug: GS-9669 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9669 500 mg QD
Trial: 25155588
Drug: GS-9669 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9669 500 mg BID
Trial: 25155604
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DTG once daily for 5 days
Trial: 25155604
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DTG once daily in combination with 700/100 mg FPV-RTV every 12 h for 10 days
Trial: 25156560
Drug: tetanus-diphtheria-acellular pertussis
RxNorm normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetanus-diphtheria-acellular pertussis vaccine
Trial: 25157214
Drug: Sugammadex 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4.0 mg/kg administered at least 15 min after the last dose of rocuronium
Trial: 25162465
Drug: sEH inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEH inhibitor (sEHI)
Trial: 25163595
Drug: Neoadjuvant IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant IMRT (median dose 50 Gy, 26-55) followed by surgery and IOERT (10-12 Gy)
Trial: 25164021
Drug: PDC31 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC31 (1 mg/kg/h)
Trial: 25164021
Drug: PDC31 (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC31 (0.01, 0.05, 0.15, 0.3, 0.5, 1 mg/kg/h)
Trial: 25164234
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m(2) intravenously on day 1, and irinotecan 80 mg/m(2) on days 1 and 8, of a 21-day cycle up to 15 cycles or until disease progressed.
Trial: 25164234
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and irinotecan combination treatment.
Trial: 25164945
Drug: Spironolactone therapy
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone therapy added to a standard heart failure regimen
Trial: 25165428
Drug: Methylnaltrexone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone administered every other day for up to fourteen days.
Trial: 25166023
Drug: Canagliflozin 30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 30, 100, 200, or 400 mg once daily or 300 mg twice daily, or placebo
Trial: 25166484
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride (HCL), 200 to 300 mg/d, twice-daily immediate-release
Trial: 25167069
Drug: Intervention: Detoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Detoxification treatment for alcohol use disorder
Trial: 25167216
Drug: Anti-TNFα therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα therapy (adalimumab)
Trial: 25167216
Drug: Anti-IL-6R therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-IL-6R therapy (tocilizumab)
Trial: 25169854
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.5 mg/kg over 40 min)
Trial: 25170013
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily) and Dasatinib (70 mg daily)
Trial: 25170123
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL1/ABL ≤10% at 3 months
Trial: 25170123
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL1/ABL >10% at 3 months
Trial: 25170245
Drug: TRAV/TIM-FC (travoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAV/TIM-FC (travoprost 0.004%/timolol 0.5%) administered once daily at 8 pm for 4-6 weeks
Trial: 25171955
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid users
Trial: 25173458
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus sorafenib (sorafenib at 400 mg/bid, TACE with lipiodol, 50 mg doxorubicin, and PVA particles repeated q6w)
Trial: 25174587
Drug: CD33-directed chimeric
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Trial: 25175077
Drug: Caries risk
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caries risk assessment (CRA) decision based on oral hygiene in pediatric patients